Invitrogen™ Human RARRES2/TIG2 ELISA Kit

Beschrijving

The Human RARRES2/TIG2 ELISA quantitates Hu RARRES2 in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu RARRES2. Principle of the method The Human RARRES2 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

Retinoids act through ligand-dependent transcription factors, retinoid X receptor (RXRs) and retinoic acid receptors (RARs). Tazarotene-induced gene (TIG) proteins, also designated retinoic acid receptor responder proteins or RAR-responsive proteins, can be membrane bound or secreted. TIGs act as tumor suppressor genes in human cancers and are highly expressed in skin, hair follicles and endothelial cells as well as in pancreas, spleen and intestine. TIGs are activated by tazarotene and have been implicated as growth regulators that mediate the growth suppressive effects of retinoids. TIG2 is a secreted protein that is mainly expressed in epidermis, hair follicles and endothelial cells. TIG2 is inhibited in psoriatic lesions and is activated by tazarotene in skin rafts and in epidermis of psoriatic lesions.